Mr. Matthew Walsh currently serves as Executive Vice President and Chief Financial Officer of Organon & Co., a global pharmaceutical business within Merck that is planned to be spun off in 2021. Prior to Organon, he served as Executive Vice President and Chief Financial Officer of Allergan, a publicly traded, global biopharmaceutical company, from 2018 until the sale of the company to Abbvie in 2020. From 2008 to 2018, Mr. Walsh served as Chief Financial Officer of Catalent, a global provider of delivery technologies, development, and manufacturing solutions to the life sciences industry. During his tenure, Catalent successfully completed the largest healthcare IPO of 2014. Before Catalent, from 2006 to 2008, he was President, Chief Financial Officer and Acting Chief Executive Officer at Escala Group, Inc.
Mr. Walsh previously held a variety of finance leadership roles at industrial manufacturer GenTek, Inc., including Chief Financial Officer, Treasurer, and Group Controller. He served on the board of directors of Multicolor Corporation from 2015 to 2017.
Mr. Walsh earned his Bachelor of Science degree in chemical engineering from Cornell University, and an M.B.A. from Cornell University, SC Johnson School of Management. Mr. Walsh is a CFA® charterholder.